CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Giaconda Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Giaconda Ltd
44 East Street
Ground Floor, Five Dock
Phone: +61 293700069p:+61 293700069 SYDNEY, NSW  2046  Australia Fax: +61 297121469f:+61 297121469
This company is no longer actively traded on any major stock exchange.
Business Summary
Giaconda Limited (Giaconda) is an Australia-based company. The Company is engaged in the development and commercialization of therapies for gastrointestinal diseases and disorders. It operates from Sydney, New South Wales, Australia. It will conduct clinical trials in the United Kingdom, Australia, Europe and North America. Myoconda is a triple antibiotic therapy to treat moderate to severe Crohn’s disease. Hepaconda is a dual therapy to treat Hepatitis C virus, especially genotype one. Heliconda is a triple therapy to treat resistant Helicobacter pylori infection. Ibaconda is a dual therapy to treat constipation predominant Irritable Bowel Syndrome. Picoconda1 is a bowel preparation designed to reduce the poor taste of present bowel preparation products. On August 16, 2010, the Company entered into an agreement to sell all of the intellectual property in Myoconda, Picoconda and Heliconda.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20106/30/2010Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Acting Chairman of the Board, Chief Executive Officer, Executive Director Patrick L.Mclean 10/20/2008 11/16/2004
Chief Medical Officer, Executive Director Thomas J.Borody 2/23/2004 2/23/2004
Company Secretary MargauxAlvaran 2/5/2010 2/5/2010
Independent Non-Executive Director Christopher R.Bilkey 1/19/2009 1/19/2009
Independent Non-Executive Director TrevorMoore 12/14/2004 12/14/2004

Business Names
Business Name
Giaconda Limited
Giaconda Ltd

General Information
Number of Employees: 1 (As of 6/30/2010)
Outstanding Shares: 78,373,505 (As of 1/12/2011)
Shareholders: 656
Stock Exchange: ASX
Fax Number: +61 297121469


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023